Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02458677 · ClinicalTrials.gov registry record · Phase 1
Single Ascending Dose Study of PRX003 in Healthy Subjects
A Phase 1 study of Psoriasis, sponsored by Prothena Biosciences Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT02458677: Completed Phase 1 study of Psoriasis, sponsored by Prothena Biosciences Limited.
NCT02458677 is a Phase 1 study of Psoriasis that has completed, run by Prothena Biosciences Limited. The registered enrollment target is 40 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02458677, a Phase 1 study of Psoriasis, has completed, sponsored by Prothena Biosciences Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This single ascending dose study is to determine safety, tolerability, pharmacokinetics and immunogenicity of PRX003 in approximately 40 healthy subjects.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG PRX003
Study Locations (1)
Texas
- Worldwide Clinical Trials Early Phase Services - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2015-05 |
| Est. Completion | 2016-02 |
| Phase | Phase 1 |
What the finished NCT02458677 record still lists
NCT02458677 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02458677 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02458677 about?
NCT02458677 is a clinical study titled "Single Ascending Dose Study of PRX003 in Healthy Subjects". This single ascending dose study is to determine safety, tolerability, pharmacokinetics and immunogenicity of PRX003 in approximately 40 healthy subjects.
What is the current status of trial NCT02458677?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2015-05. Estimated completion is 2016-02.
What conditions does trial NCT02458677 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT02458677?
The interventions under investigation include: Placebo (OTHER), PRX003 (DRUG).
Who is sponsoring clinical trial NCT02458677?
This trial is sponsored by Prothena Biosciences Limited, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02458677 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02458677's enrollment target sits among peer trials
40 83rd of 125 higher than 40 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118
RECRUITING · Phase 1
-
Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques
RECRUITING · Phase 1
-
Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis
RECRUITING · Phase 1
-
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
COMPLETED · Phase 1
-
Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia